Craig Caldwell, MD
Internal Medicine · Forsyth, GANPI 1801981592
Payments from drug & device makers
Across 129 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$302
- Astellas Pharma US Inc$276
- Pfizer$237
- Lilly USA, LLC$229
- Novo Nordisk$181
- Amgen$179
- plus $894 from 21 others
What the payments were for
- Food & beverage$2,298100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $302 |
| Astellas Pharma US Inc | 20 | $276 |
| Pfizer | 14 | $237 |
| Lilly USA, LLC | 13 | $229 |
| Novo Nordisk | 9 | $181 |
| Amgen | 11 | $179 |
| Novartis | 7 | $133 |
| Gilead | 1 | $121 |
| Merck | 6 | $91 |
| Exact Sciences | 5 | $81 |
| GSK | 4 | $68 |
| Boehringer Ingelheim | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| AbbVie(2 entities) | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Mylan Specialty L.p. | 1 | $28 |
| Seqirus USA Inc | 1 | $23 |
| Corcept Therapeutics | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Bausch Health US, LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Truvada$121
How this compares
$2,298 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $102,095 |
| OzempicSemaglutide | 93 | $88,287 |
| JardianceEmpagliflozin | 95 | $72,611 |
| TrulicityDulaglutide | 30 | $36,478 |
| JanuviaSitagliptin Phosphate | 32 | $26,654 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 32 | $25,368 |
| MounjaroTirzepatide | 24 | $24,897 |
| XareltoRivaroxaban | 19 | $19,527 |
| FarxigaDapagliflozin Propanediol | 34 | $18,263 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $15,457 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $13,371 |
| MyrbetriqMirabegron | 13 | $11,772 |
| InvokanaCanagliflozin | 17 | $9,570 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,508 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $6,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $237 | $102,095103 claims |
| Novo NordiskOzempic | $181 | $88,28793 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $64 | $88,068108 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $229 | $61,37554 claims |
| MerckJanuvia, Janumet Xr | $91 | $52,02164 claims |
| Johnson & JohnsonXarelto, Invokana | $14 | $29,09736 claims |
| AstraZenecaFarxiga, Symbicort | $302 | $22,56049 claims |
| Astellas Pharma US IncMyrbetriq | $276 | $11,77213 claims |
| GSKAnoro Ellipta | $68 | $7,50815 claims |
| AbbVieSynthroid | $40 | $1,71616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Forsyth
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.